Perioperative Chemoimmunotherapy in NSCLC: From Clinical Trials to Practice

Watch the full conversation on Oncology Data Advisor: https://oncdata.com/perioperative-chemoimmunotherapy-nsclc-meir-aung Perioperative chemoimmunotherapy has rapidly moved from clinical trials into practice for patients with resectable non–small cell lung cancer (NSCLC), yet real-world implementation remains a challenge. In this discussion, Wint Yan (Arthur) Aung, MD, and Juliet Meir, MD, Hematology/Oncology Fellows at Northwell Health, explore how to optimize these strategies to improve patient outcomes. Dr. Meir outlines the clinical rationale for perioperative care, including improved major pathologic response rates and overall survival. She addresses common clinical concerns, such as treatment-related fibrosis and the risk of delayed or missed surgery, while emphasizing how multidisciplinary coordination between thoracic surgeons, medical oncologists, and pulmonologists can mitigate these risks. The conversation also highlights Northwell Health’s quality improvement initiative to increase referral rates and the importance of nuanced patient selection, particularly for those with actionable driver mutations like EGFR or ALK. Looking ahead, the experts discuss the role of biomarkers and ctDNA in creating risk-adapted, personalized perioperative pathways that maintain the curative potential of surgery.